Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

Go back to Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
(NASDAQ: BBIO) Delayed: 67.74 +0.19 (0.28%)
Previous Close $67.55    52 Week High $ 
Open $68.04    52 Week Low $ 
Day High $68.79    P/E N/A 
Day Low $67.55    EPS $ 
Volume 3,036,099